Lymphoma Patients' brain function under microscope after new cell therapy

NCT ID NCT04319237

Completed Knowledge-focused Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 60 adults with diffuse large B-cell lymphoma or transformed lymphoma who received commercial axi-cel therapy. Researchers measured changes in memory, attention, executive function, hand strength, and quality of life using surveys and cognitive tests. The goal was to better understand the real-world side effects of this treatment on brain function and daily living.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axicabtagene ciloleucel (axi-cel)
What this could lead to: If successful, this study could help doctors better understand and manage the cognitive and emotional side effects of axi-cel therapy, improving patient support.
What could go wrong: This is an observational study with no new treatment being tested. It only measures outcomes in a small group (60 people) and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma primary mediastinal large B-cell lymphoma Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA TRANSFORMED LYMPHOMA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.